Modified cyclodextrins for the targeted delivery of siRNA for prostate cancer therapy

Show simple item record

dc.contributor.advisor O'Driscoll, Caitriona M. en
dc.contributor.author Evans, James C.
dc.date.accessioned 2017-05-18T11:49:12Z
dc.date.issued 2017
dc.date.submitted 2017
dc.identifier.citation Evans, J. C. 2017. Modified cyclodextrins for the targeted delivery of siRNA for prostate cancer therapy. PhD Thesis, University College Cork. en
dc.identifier.endpage 329 en
dc.identifier.uri http://hdl.handle.net/10468/3991
dc.description.abstract Prostate cancer is the most common non-cutaneous cancer in men of the western world. When the disease is confined to the prostate gland there are many effective treatment options for the disease, some of which are even curative. In contrast, the metastatic disease is far more difficult to treat, with current therapies offering only a modest increase in overall survival and significant morbidity. In light of this, an effective therapy for metastatic prostate cancer is an unmet clinical need. RNA interference (RNAi) has emerged in recent years as a potential therapy for a wide range of disease states including cancer. However, the clinical application of RNAi is challenging. The main barrier to an effective therapy is the lack of a suitable delivery vector. Cyclodextrins are cyclic oligosaccharides that have emerged in recent years as highly effective gene delivery vectors. The main aim of this thesis was to develop a range of formulations containing modified cyclodextrins that are targeted to prostate cancer and to assess the effect of silencing therapeutically relevant genes on the metastatic potential of prostate cancer cells. A series of modified targeted cyclodextrins were assessed in various models of prostate cancer. These include 2D-cell monolayers, 3D collagen-based scaffold cultures, spheroid models and in vivo models. The resulting formulations resulted in superior delivery of siRNA to prostate cancer cells. In addition, it was shown that the inclusion of the cell-penetrating peptide, octaarginine or the fusogenic peptide, GALA into the formulations led to a superior level of knockdown of the target genes. In conclusion, we have successfully developed a range of cyclodextrin formulations that exhibit receptor mediated targeting in prostate cancer cell lines and that have potential for use in vivo. en
dc.description.sponsorship Irish Cancer Society (CRS12EVA) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher University College Cork en
dc.rights © 2017, James C. Evans. en
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/ en
dc.subject Prostate cancer en
dc.subject RNAi en
dc.subject Nanoparticles en
dc.subject Cyclodextrin en
dc.subject Targeted therapy en
dc.title Modified cyclodextrins for the targeted delivery of siRNA for prostate cancer therapy en
dc.type Doctoral thesis en
dc.type.qualificationlevel Doctoral en
dc.type.qualificationname PhD (Science) en
dc.internal.availability Full text not available en
dc.check.info Indefinite en
dc.check.date 10000-01-01
dc.description.version Accepted Version
dc.contributor.funder Irish Cancer Society en
dc.description.status Not peer reviewed en
dc.internal.school Pharmacy en
dc.check.reason This thesis is due for publication or the author is actively seeking to publish this material en
dc.check.opt-out Not applicable en
dc.thesis.opt-out false
dc.check.entireThesis Entire Thesis Restricted
dc.check.embargoformat Both hard copy thesis and e-thesis en
ucc.workflow.supervisor caitriona.odriscoll@ucc.ie
dc.internal.conferring Summer 2017 en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

© 2017, James C. Evans. Except where otherwise noted, this item's license is described as © 2017, James C. Evans.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement